Assure Holdings Performs First Neuromonitoring Case in Texas
- Validates Platform Scalability in States Outside of Colorado -
PARKER, Colo., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSX-V:IOM) (OTCQB:ARHH), a provider of intraoperative neuromonitoring services, has performed its first neuromonitoring case in the state of Texas.
“The completion of our first case in Texas is an important milestone for our company, as it validates our strategy to expand our unique neuromonitoring platform outside of Colorado,” said Preston Parsons, founder and chairman of Assure. “Our new director of business development, George Sims, was instrumental in securing this relationship, drawing upon his more than 26 years of experience in the medical device industry.
“Texas was a top priority due to George’s strong relationships in this area, as well as the state’s attractive demographics. Given the fact that entering a new market and performing the first case is often the most challenging and time-consuming task, we are confident in our ability to accelerate future relationships in this great state.”
The Company is growing rapidly by uniquely providing a turnkey suite of neuromonitoring services administered by its own staff of highly-qualified technologists. Assure also handles all scheduling and setup, and bills for all technical services provided. Given this unique platform and additional opportunities for expansion in other states, Assure believes significant opportunities for further long-term growth lie ahead.
About Assure Holdings
Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. While Assure focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. For more information, visit the company’s website at assureIOM.com.
This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Assure anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, comments with respect to strategies, expectations, planned operations and future actions of the Company. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Assure to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to Assure, including information obtained from third-party industry analysts and other third-party sources, and are based on management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement.
Matthew Willer, President
Cody Slach, Managing Director
Liolios Investor Relations
Released November 13, 2017